Actively Recruiting
Prevalence and Clinical Severity of Autoimmune Blistering Diseases at University of Pennsylvania
Led by University of Pennsylvania · Updated on 2026-03-30
150
Participants Needed
3
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the severity and impact of autoimmune blistering diseases, specifically pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid. These diseases cause severe blistering and require new ways to measure disease severity accurately for use in clinical trials. The study aims to validate two key disease severity instruments, the Pemphigus Disease Area Index (PDAI) and the Bullous Pemphigoid Disease Area Index (BPDAI), against other measures and to understand how these relate to patients' quality of life. Participants will complete several questionnaires, including the PDAI, BPDAI, the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS), and various quality of life assessments such as the SF-36, Skindex-29, Dermatology Life Quality Index (DLQI), Autoimmune Bullous Disease Quality of Life (ABQOL), and Treatment of Autoimmune Bullous Disease Quality of Life (TABQOL). Blood samples may also be donated to a blood bank for further immunologic and pathophysiologic studies. The study is observational and data is securely stored within a password-protected database. During the study, participants will be asked to rate their disease severity and complete quality of life questionnaires over a one-year period. The research team will use these assessments to compare disease severity scores and quality of life impacts. This study is conducted at the University of Pennsylvania and involves ongoing data collection to support future clinical trials for these conditions.
CONDITIONS
Brief Title
Autoimmune Blistering Diseases Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 years or older
- Diagnosed with pemphigus vulgaris, pemphigus foliaceus, or bullous pemphigoid
- Able to give informed consent
You will not qualify if you...
- Under 18 years of age
- No diagnosis of pemphigus or pemphigoid diseases
- Employees of the University of Pennsylvania
- Students at the University of Pennsylvania
- Cognitively impaired individuals
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year
Participants complete questionnaires and assessments to evaluate disease severity and quality of life over time.
Periodic visits for assessments during the study period
Trial Site Locations
Total: 3 locations
1
Hospital of the University of Pennsylvania, Department of Dermatology
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
2
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
3
University of Pennsylvania, Department of Dermatology
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
V
Victoria P Werth, MD
J
Joyce Okawa, RN
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here